
India Pesticides Q4 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
No
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- India Pesticides Limited projects a revenue of around INR 1,000 crores for FY '26, with capacity utilization currently at 61%, indicating room for scaling beyond this target if demand rises.
- The company anticipates a 15% to 20% CAGR revenue growth over the next 2-3 years, supported by capacity expansion and new product additions.
- Export contributions are expected to remain stable around 38-40% of total revenue, with focus on a balanced product mix catering to both domestic and international markets.
- Capacity expansions at Sandila and Hamirpur facilities will support growth, with peak revenues estimated around INR 1,100 crores from Sandila alone.
- Growth drivers include backward integration, new product registrations in regulated markets (EU, USA, Australia), and increased formulations business, especially bulk formulations exports showing over 20% YoY growth.
- Continuously expanding distribution network in India and improving demand from regulated export markets will fuel volume growth.
See what India Pesticides management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- India Pesticides Limited currently maintains a strong balance sheet with low debt levels (total debt increased from INR 18 crore in FY '24 to INR 52 crore in FY '25, mainly short-term borrowings expected to normalize soon).
- The company is committed to funding all expansion and capital expenditure from internal accruals and maintaining a debt-free position.
- Planned capex of INR 116 crore for FY '26 is funded internally, with no mention of new fundraising through debt or equity.
- Management focus remains on operational growth and capacity expansion without plans for external fundraising.
- There was no indication or discussion about imminent equity fundraising or debt issuance during the call.
See what India Pesticides management said on order book — free account, 30 seconds.
Capex plans
Yes- Planned Capex for FY '26: INR 116 crore for India Pesticides and its 100% subsidiary Shalvis Specialities Limited.
- Capex includes:
- - Expansion at Sandila site (INR 52 crore portion) for increasing capacity, adding a boiler, one intermediate, and one technical product complex.
- - New production blocks to manufacture new products not possible in existing blocks.
- Two-year targeted capex exceeds INR 200 crore.
- Hamirpur facility progressing well, expected to contribute to gradual revenue and profitability increase over coming years.
- Capex funded primarily through internal accruals, maintaining a debt-free position.
- Strategic efforts include backward integration to improve margins, ramping up production, and diversifying product portfolio.
- Exploration under CRDMO initiative to collaborate with international companies for scaling research products commercially.
Track India Pesticides — get its next earnings analysis in your feed
How does India Pesticides rank vs peers in Fertilizers & Agrochemicals?
Pro featureHow does India Pesticides rank in Fertilizers & Agrochemicals?
Compare India Pesticides against every Fertilizers & Agrochemicals company (Q4 FY25) on revenue, margins and earnings-call signals.
Continue your research
What India Pesticides's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- Madhya Bharat Agro Products (Q2 FY27)
Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo
- Dhansa Labs (Q2 FY27)
1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Aristo Bio-Tech (Q2 FY27)
1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu
- Krishana Phoschem (Q2 FY27)
Q2 FY27 Revenue: ₹703 crore, a 16% year-on-year (YoY) increase (Page 11). Key investor presentation takeaways from Krishana Phoschem Ltd's Q2 FY27 investor pres